Plain-English translation of NCT06712927 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three immunotherapy medications—relatlimab, nivolumab, and —to treat melanoma that has spread to the brain. The study includes two groups: patients who don't have symptoms from their brain tumors and patients who do have symptoms. Researchers want to see if this three-drug combination can shrink or control these brain tumors.
Melanoma that spreads to the brain is very difficult to treat, and current options are limited. This medication combination works by boosting the immune system to fight cancer cells, and this trial will test whether it can be effective specifically for brain metastases.
You likely qualify if…
You likely don't qualify if…
If you're eligible, you'll receive the three-drug combination through intravenous infusions at a research hospital or clinic. The study divides participants into two groups based on whether you have brain tumor symptoms. You'll have regular visits to receive the medication, undergo imaging scans to see how your tumors respond, and have blood tests to monitor your health. The trial will track your progress over time to evaluate how well the treatment works and how safe it is.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States